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Liver transplantation for hepatocellular 
carcinoma 
D. H. VAN THIEL, V. DINDZANS, J. S. GAVALER, L. MAKOWKA AND 
T.E.STARZL 
According to the U.S. National Cancer Institute, 13600 new cases of 
malignant tumours of the liver and biliary tree were expected to occur within 
the United States in calendar year 19861• This incidence is rather low 
compared to many other more populous areas of the world such as Southeast 
Asia and Japan (Table I) where the incidence of hepatitis B virus (HBV) 
infection and, as a result hepatocellular carcinoma (HCC), is more common. 
HBV is responsible for greater than 80% of the cases of HCC worldwide such 
that HBs Ag-positive carriers have a 200-fold greater risk of developing HCC 
than do Ag-negative controls and as many as 50% of all carriers may develop 
HCC. The risk of becoming a carrier for HBV is inversely related to the age at 
which the HBV infection occurs, being> 85% for infected newborns and 
< 10% for adults. Chronic hepatitis B viral infection with macronodular 
cirrhosis and integration of the hepatitis B virus a~ A into the liver cell 
genome is not the only cause of hepatocellular carcinoma in the world, 
however. Hepatoma is a rather common consequence of a larger number of 
chronic liver diseases and occurs in such diseases at a variable rate between I 
and 100% depending upon the type of cirrhosis and the nature of the under-
lying liver disease (Table 2). 
Table I Annual incidence of hepatocellular carcinoma 
Rare Incidence (per 100000) Location 
Very high 
High 
Intermediate 
Low 
> 20 
10-20 
5-9 
5 
China. Southeast Asia. South Africa (Blacks) 
Japan. Southern Europe, Switzerland. Bulgaria 
East Europe. France. Germany. Yugoslavia 
Great Britain. United States, Australia. New 
Zealand, Latin America, India, Sri Lanka 
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LIVER CELL CARCINOMA 
Table 2 Rate of hepatocellular carcinoma as 
a consequence of cirrhosis 
Disease Rale 
Macronodular cirrhosis 40-55% 
Micronodular cirrhosis 3-10% 
Alcoholic cirrhosis 15% 
Haemochromatosis 17-25% 
Alpha-I-antitrypsin deficiency 1% 
Tyrosinaemia 100% 
Wilson's disease 1% 
Primary biliary cirrhosis 1% 
Environmental factors other than viral infection also contribute 
importantly to tbe prevalence of hepatocellular carcinoma worldwide. These 
additional environmental factors include the therapeutic use of sex steroids, 
particularly oral contraceptives, nutritional deficiency states, fungal myco-
toxin contamination of cereal products and of industrial exposures experi-
enced in the workplace (Table 3). 
The optimal treatment for hepatocellular carcinoma is partial or subtotal 
hepatectomy vK;~ preservation of as much normal residual hepatic tissue as is 
possible. This can be accomplished by experienced surgeons with a quite low 
mortality ratec. ~{ortality rates, however, vary considerably in various series 
and range betv.een 5 and 30%3. The extent of the resection as well as the 
indication for the resection and the severity of the underlying liver disease 
present in a given patient importantly affect the mortality experienced with 
Tabk 3 Environmental factors contributing to the develop-
ment of hepatocellular carcinoma 
Oestrogens 
Especially oral contraceptive agents, with an estimated 
500-fold increased risk after 85 months of use 
.. \ vailable steroids 
Dietary restriction 
Protein 
Methionine 
Selenium 
Zinc 
Folic acid 
Vitamin 8 12 
Aflatoxins 
• Industrial Exposure 
Arsenic 
Vinyl chloride 
Other agents less well-characterized 
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T.ble 4 Types of hepatic resections 
• Right on left hepatic lobectomy - gall bladder fossa and lye 
• Left lateral segment - falciform ligament 
•• Right trisegmentectomy - all of true right lobe and medial segment of left lobe 
• Left trisegmentectomy - all of true left lobe and the anterior segment of the right ;obe 
• Total hepatectomy with orthotopic transrlantation 
.. Wedge resection - does not follow anat0mic planes; usually reserved for benign lesions 
such resections. The various types of hepatic resection possible are shown in 
Table 4 and Figure I. Unfortunately, although hepatic resection is the only 
curative procedure for hepatocellular carcinoma, < 50% of cases explored are 
resectable either because of underlying cirrhosis or the size and! or location of 
the tumour and < 20% of explored cases are totally resectable despite the 
application of new surgical techniq ues such as intra-operative ultrasonic local-
ization and dissection of the tumour. the hepatic vessels and the biliary tree. 
Total hepatectomy followed by orthotopic liver transplantation is currently 
the only hope for cure in those patients with underlying cirrhosis or with 
extensive tumour burdens that preclude standard large hepatic resections 
(Table 4 and Figure I). Liver transplantation has been applied to the problem 
of hepatic malignancy ever since the first clinical applications of the 
procedure4- 6• Shown in Figure 2 is the accumulative survival rate for more 
than 800 adult transplant recipients operated upon at the University Health 
LT. LATERAL SEGMENTEC'lUMY NON·ANATOMICAL MSECTION 
LEfT LOBECTOMY RIGHT LOBECTowY (J)7' .... I' : I . 
.. 
L T. TRISEGMENTEC'TtVI' RT. TRISEGMEHTEC'TOMY 
Ficure I Schematic representation of the types of major hepatic resections possible with good 
survival 
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Figure 2 Kaplan-Meier survival curves for 800 adult liver transplant recipients (--) and a 
subset of 70 recipients transplanted because of a hepatic malignancy (- - - -) 
Center of Pittsburgh for all indications except hepatic malignancy and the 70 
patients transplanted for a malignant tumour of the liver at the same 
institution by the same surgeons, using the same immunosuppressive 
. 7 
regImens. 
The percentage of patients transplanted for hepatic malignancy at a given 
institution varies markedly depending upon a variety of factors including the 
longevity of the programme, the approach of the institution to patients with 
HBsAg positivity and cholangiolar carcinoma and the numbers of patients 
being referred for transplantation for other indications6- 9 . In the Denver-
Pittsburgh experience during the pre-cyclosporine era, \3.5% of all recipients 
had hepatic malignancy as the indication for their procedure. In more recent 
times, following the introduction of cyc\osporine and as a result of more cases 
being referred for indications other than hepatic malignancy, the percentage 
of cases transplanted for hepatic malignancy has fallen by 50% to 6.8%10. In 
contrast to the experience in the United States, the experience in Europe has 
included a larger percentage (29%) of cases with hepatic malignancy as the 
indi cation for transplantation. In some European centres, a full one-third of 
the patients transplanted have had a hepatic malignancy as the indication9 • 
The experience with hepatic transplantation for malignancy at these 
various centres throughout the world has been very similar to that reported 
by the Pittsburgh group with long-term survival (> 3 years after transplanta-
tion) being between 20 and 30q (Figure 2). This survival figure is one-half to 
one-third that experienced for all other indications for which liver transplanta-
tion has been applied but is nonetheless considerably better than that . 
experienced with any other type of therapy, particularly medical therapy 
where no survivors exist after one year1) • 
502 
LIVER TRANSPLANTATION FOR HCC 
Table 5 Co-existent liver disease in 21 patients with 
incidental primary liver neoplasms 
Disease 
Cirrhosis 
Tyrosinaemia 
Biliary atresia 
Sclerosing cholangitis 
Alpha-I-antitrypsin deficiency 
F amiliary cholestasis 
Sea-blue histiocyte syndrome 
Number ojpolienls 
5 
4 
4 
4 
2 
The experience with liver transplantation applied for hepatocellular 
carcinoma is not entirely grave_ Individuals who have been transplanted for 
other conditions in which a hepatic malignancy typically < 5cm in diameter 
was found (Table 5) have done very well and have had a survival rate similar 
to that experienced by those transplanted for the same condition not compli-
cated with a hepatic cancer (Figure 3). Of the 14 such cases, all but one has 
survived without re-occurrence of their hepatocellular carcinoma with the 
duration of follow-up ranging from 3 to 73 months and with 6 of these 13 
long-term survivors being free of recurrent disease beyond 3 years. 
In contrast to the experience with hepatocellular carcinoma occurring 
'incidentally' in a liver at the time of hepatic transplantation, the clinical 
course of those transplanted solely because of hepatocellular carcinoma has 
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Filure 3 Kaplan-Meier survival curves for liver graft recipients to have an incidental hepatic 
neoplasm in a liver remo·ved for another reason (--) and those transplanted for hepatic 
malignancy (- - - -) 
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been quite different. Among 20 such patients transplanted during the cyclo-
sporine era, 5 (25%) died during the immediate post-operative period (within 
2 months of transplantation); 8 of the remaining 15 (53%) developed 
recurrent disease at intervals of 4-12 months following transplantation. 
Recurrence of the hepatoma in the allograft was the first evidence of disease. 
recurrence in 50% of the cases, in 38% of recurrent cases the recurrence 
occurred first in the lungs and 12% it occurred first in bone. Of the remaining 
8, 2 have survived for only I and 8 months, respectively, while 6 have survived 
free of recurrent disease for intervals ranging from 6 to 54 months. 
A recent report extracted from the European Liver Transplant Registry 
reported a 30% survival for patients transplanted for hepatocellular 
carcinoma at 2 years8. The data compiled by Pichlmayr9 from 7 major 
European centres is quite similar to that experienced in Pittsburgh with 30% 
of the patients surviving for I year but only 17% surviving free of disease for 
> 2 years. 
These results from Europe and the United States clearly document that 
despite the elimination of patients with extra-hepatic malignancy detected by 
a careful screening of each candidate for metastatic disease with computed-
tomography scans of the chest, abdomen, and head as well as with bone 
scanning techniques, that microscopic metastasis, unrecognized either before 
surgery and at the time of the transplant procedure itself persists in such cases 
despite resection of the gastro-hepatic and hepato-duodenal ligaments, 
skeletalization of all vascular structures as well as the common bile duct and 
resection of the bile duct as it crosses behind the duodenum with the creation 
of a roux-en-Y choledochojejunostomy. 
At this point in time, the results with the application of adjuvant chemo-
therapy after the hepatectomy during the anhepatic phase of the transplant 
procedure and in the first several months following liver transplantation for 
hepatoma are not yet available. The experiences with such modifications of 
current techniques are either being formulated now, or at least in some cases 
are only beginning to be accumulated. 
The exception to the rule of a poor prognosis with hepatic transplantation 
for hepatocellular carcinoma is the experience with fibrolamellar carcin-
oma l4• Typically, this tumour occurs in young adults and in the absence of 
any underlying liver disease. Moreover, it reportedly grows slowly, has a high 
resectability rate, and therefore, a longer survival rate than that experienced 
with other types of hepatocellular carcinoma I2- 14• A total of 9 patients with 
this variant of hepatocellular carcinoma have been treated by the Pittsburgh 
group during the cyclosporine era with orthotopic liver transplantation. None 
of them had distant metastasis at the time of transplantation although 2/9 
had tumour infiltrating the diaphragm which necessitated excision of a part 
of the diaphragm with the liver and the tumour; 3 of the tumours (33%) 
showed some degree of vascular invasion of the resection specimen. One-third 
of these patients died early as a result of one or another non-tumour-related 
surgical problems. Of the remaining 6, 2 have died as a result of recurrent 
disease at 32 and 33 months post-transplant, while 4 are alive with only I 
having evidence of recurrent disease with a mean duration in survival of 30 
months. 
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There has been no reported experience with the particular tumour variant 
in the data available from the European Liver Transplant Registry8,9. The 
available American experience however, suggests that a limited number of 
pulmonary metastases may not be a contraindication for liver transplantation 
./ ,in this sub-group and that an aggressive approach to recurrent disease with 
additional resectional surgery and chemotherapy may be possiblel4• 
! Yet another unique type of hepatic malignancy that may be amenable to 
fl. liver transplantation is the recently relatively recognized epithelioid haem-
angioendothelioma1s- 17 • Characteristically, this tumour grows slowly like the 
fibrolamellar variant with a natural history that spans 5- I 0 years despite 
metastasis to bone, lungs, pleura and lymph nodes: 6 cases of this tumour 
have been transplanted in Pittsburgh; 2 had known distant metastatis (1 to 
the lung and I to a rib) prior to transplantation; 4 had extra-hepatic intra-
abdominal disease recognized at surgery but not pre-operatively (3 in lymph 
nodes and I involving the diaphragm). All 6 have survived with follow-ups 
ranging from JO to 49 months (mean 22 months). The 2 with distant 
metastasis have had their disease remain stable. Because the natural history of 
this disease is so unusual, it is not yet possible to make a definitive statement 
about the role of transplantation in such cases. 
Bile-duct cancers comprise 16% of the tumours for which liver transplanta-
tion has been applied in the Pittsburgh experience. On average, these patients 
are older than the other tumour patients and 72% have had primary 
sclerosing cholangitis as the underlying chronic liver disease. Half have also 
had ulcerative colitis. In 55% of the cases, particularly those with sclerosing 
cholangitis, the tumour was not identified prior to hepatic resection despite 
an extensive pre-operative evaluation including brushing of the bile ducts for 
cytologic examination being obtained from the involved biliary tree whenever 
possible. Overall, 11% of the cases transplanted for sclerosing cholangitis 
had not been cholangiolar carcinoma 18: 18% of these patients died early in the 
post-operative course; 78% of the survivors however, developed clinically-
evident recurrent disease on mean at 8.5 months post-transplantation. Only 
22% have survived> 15 months without recurrent disease. The experience of 
the Cambridge group with this tumour has been similar to that experienced in 
Pittsburgh l9. The data of Pichlmayr suggest that those with nodal metastasis 
at the time of transplantation do very poorly, with only 13% being alive at I 
year and none at 2 years, while 100% of those without nodal metastasis are 
alive at I year and 83% are alive at 2 years following transplantation9. 
'/ 
It is clearly evident from the above data that the results with total 
hepatectomy and orthotopic liver transplantation for the treatment of hepatic 
malignancy currently are less than ideal. Increasing surgical experience with 
the procedure and the use of cyclosporine has resulted in fewer immediate post-
operative deaths such that the application of this mode of therapy can be 
more clearly evaluated. In general, particularly when compared to the results 
experienced with non-malignant diseases of the liver, the results have been 
poor, with only 20-30% of the patients surviving for periods> I year. 
Progress in this area awaits the development of new chemotherapeutic agents 
that are effective against hepatocellular carcinoma or the development of 
,j j 
means of targeting and destroying microscopic metastatic foci of malignant 
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disease once the bulk of the tumour load is removed as a result of the total 
hepatectomy. 
Current recommendations are that liver transplantation be applied to those 
patients with hepatic malignancy such as the fibromellar variant and the more 
unusual epithelioid haemangioendothelioma and occasionally for those with • , 
other types of hepatocellular but not biliary epithelial tumours, who have .. 
extra-hepatic malignancy ruled out by means of computed tomography 
scanning of the chest, abdomen and head and a bone scan followed either by oJ 
a careful staging laparotomy or with a back-up candidate available for the 
allograft should the potential recipient be found to have extra-hepatic disease 
at the time of operation. 
Despite such caution, transplants are still likely to occur in patients with 
undetected extra-hepatic malignancy. The use of adjuvant chemotherapy may 
be effective in such cases. Currently, however no good data relative to this 
point exist. 
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